Sonoma Pharmaceuticals, Inc. current report, 16 December 2013

Full document

Business Context and Reporting Period

This Form 8-K is filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on December 16, 2013. The report addresses a notice of delisting received from The Nasdaq Stock Market LLC due to non-compliance with the minimum stockholders' equity requirement of $2,500,000 under Listing Rule 5550(b)(1).

Key Financial Metrics

  • Stockholders' Equity (as of Sept 30, 2013): $1,550,000 (reported in Form 10-Q).
  • Registered Direct Offering (Dec 9, 2013): 550,000 shares at $4.00/share; Gross proceeds of $2.2 million; Equity increase of $2.0 million.
  • Lender Share Sale (VLL): 617,285 shares sold by lenders at an average price of ~$5.35/share; Intended equity increase of $1.0 million.
  • Pro Forma Stockholders' Equity: $4.5 million (as of Sept 30, 2013, adjusted for recent transactions).
  • Debt and Liabilities: Proceeds from the VLL share sale are applied to eliminate put warrant liabilities and prepay remaining principal and interest on loans with VLL.

Material Changes

The Company moved from non-compliance with Nasdaq listing standards to regained compliance through two specific capital events:

  1. Completion of a registered direct offering raising $2.2 million in gross proceeds.
  2. Conversion of debt and warrant liabilities into equity via the sale of shares held by Venture Lending and Leasing (VLL), effectively reducing debt obligations and increasing equity by approximately $1 million.

Outlook, Risks, and Contingencies

Management believes the Company has regained compliance with the $2.5 million stockholders' equity requirement. However, Nasdaq will continue to monitor ongoing compliance. If the upcoming Quarterly Report on Form 10-Q for the quarter ended December 31, 2013, does not evidence continued compliance, the Company may be subject to delisting. The filing includes standard forward-looking statement disclaimers regarding risks and uncertainties.

Investor Verification Checklist

  • Verify the final audited stockholders' equity figure in the upcoming Form 10-Q for the quarter ended December 31, 2013.
  • Confirm the exact amount of debt and warrant liabilities extinguished by the VLL transaction proceeds.
  • Monitor Nasdaq communications for any further notices regarding listing status.
  • Review the impact of the $2.2 million dilution from the registered direct offering on earnings per share.